{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T15:29:37Z","timestamp":1777044577919,"version":"3.51.4"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","license":[{"start":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T00:00:00Z","timestamp":1677801600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,3,3]]},"abstract":"<jats:p>To evaluate the treatment efficacy of uterine artery embolization (UAE) using 8Spheres conformal microspheres for symptomatic uterine leiomyoma. In this prospective observational study, 15 patients were enrolled and underwent UAE by 2 experienced interventionalists from September 1, 2018, to September 1, 2019. All patients underwent menstrual bleeding scores, the symptom severity domain of the Uterine Fibroid Symptom and Quality of Life questionnaire scores (with lower scores indicating mild symptoms), pelvic contrast-enhanced magnetic resonance imaging, ovarian reserve tests (estradiol, prolactin, testosterone, follicle-stimulating, luteinizing, and progesterone), and other appropriate preoperative examinations within 1 week before UAE. During follow-up, menstrual bleeding scores and the symptom severity domain of the Uterine Fibroid Symptom and Quality of Life questionnaire scores were recorded at 1, 3, 6, and 12 months after UAE to assess the efficacy of symptomatic uterine leiomyoma. Pelvic contrast-enhanced magnetic resonance imaging was performed 6 months after the interventional therapy. Biomarkers of ovarian reserve function were reviewed at 6 and 12 months after treatment. All 15 patients successfully underwent UAE, without severe adverse effects. Six patients experienced abdominal pain, nausea, or vomiting, all of which improved significantly after symptomatic treatment. The menstrual bleeding scores declined from baseline (350.2\u2009\u00b1\u200961.9\u2009mL) to (131.8\u2009\u00b1\u200942.7\u2009mL), (140.3\u2009\u00b1\u200942.4\u2009mL), (68.0\u2009\u00b1\u200922.8\u2009mL), and (64.43\u2009\u00b1\u200917.0\u2009mL) at 1, 3, 6, and 12 months, respectively. The symptom severity domain scores at 1, 3, 6, and 12 months postoperatively were significantly lower and statistically significant compared to the preoperative scores. The uterus and dominant leiomyoma volumes decreased from baseline (340.0\u2009\u00b1\u200935.8\u2009cm<jats:sup>3<\/jats:sup>), (100.6\u2009\u00b1\u200924.3\u2009cm<jats:sup>3<\/jats:sup>) to (266.6\u2009\u00b1\u200930.9\u2009cm<jats:sup>3<\/jats:sup>), (56.1\u2009\u00b1\u200917.3\u2009cm<jats:sup>3<\/jats:sup>) at 6 months after UAE, respectively. Moreover, the ratio of leiomyoma volumes and uterus decreased from (27.4\u2009\u00b1\u20094.5%) to (18.7\u2009\u00b1\u20093.9%). At the same time, there was no significant effect on changes in the biomarkers of ovarian reserve levels. Only the changes in testosterone levels before and after UAE were statistically significant (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; .05). 8Spheres conformal microspheres are ideal embolic agents for UAE therapy. This study showed that 8Spheres conformal microsphere embolization for symptomatic uterine leiomyoma could effectively relieve heavy menstrual bleeding, improve the symptom severity of patients, reduce the volume of leiomyoma, and have no significant effect on ovarian reserve function.<\/jats:p>","DOI":"10.1097\/md.0000000000033099","type":"journal-article","created":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T20:04:11Z","timestamp":1677787451000},"page":"e33099","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["8Spheres conformal microspheres as embolic agents for symptomatic uterine leiomyoma therapy in uterine artery embolization (UAE): A prospective clinical trial"],"prefix":"10.1097","volume":"102","author":[{"given":"Yiwen","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Interventional Radiology, The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanneng","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology, The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology, The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology, The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology, The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology, The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4094-0104","authenticated-orcid":false,"given":"Guangyan","family":"Si","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology, The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"16043","DOI":"10.1038\/nrdp.2016.43","article-title":"Uterine fibroids.","volume":"2","author":"Stewart","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1067\/mob.2003.99","article-title":"High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence.","volume":"188","author":"Baird","year":"2003","journal-title":"Am J Obstet Gynecol"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.bpobgyn.2017.09.003","article-title":"Uterine artery embolization: a review of current concepts.","volume":"46","author":"Keung","year":"2018","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1056\/NEJMoa1914735","article-title":"Uterine-artery embolization or myomectomy for uterine fibroids.","volume":"383","author":"Manyonda","year":"2020","journal-title":"N Engl J Med"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.mayocp.2020.05.012","article-title":"Moving beyond reflexive and prophylactic gynecologic surgery.","volume":"96","author":"Stewart","year":"2021","journal-title":"Mayo Clin Proc"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"4676","DOI":"10.7150\/thno.42830","article-title":"Real-time and multimodality image-guided intelligent HIFU therapy for uterine fibroid.","volume":"10","author":"Ning","year":"2020","journal-title":"Theranostics"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1148\/radiol.2020204357","article-title":"Better understanding our tools for uterine fibroid embolization.","volume":"298","author":"Spies","year":"2021","journal-title":"Radiology"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1148\/radiol.2016141693","article-title":"Management of uterine fibroids: a focus on uterine-sparing interventional techniques.","volume":"280","author":"Silberzweig","year":"2016","journal-title":"Radiology"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/RLI.0b013e3182806904","article-title":"Magnetic resonance imaging-guided focused ultrasound treatment of symptomatic uterine fibroids: impact of technology advancement on ablation volumes in 115 patients.","volume":"48","author":"Trumm","year":"2013","journal-title":"Invest Radiol"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jvir.2011.10.020","article-title":"Limited efficacy of uterine artery embolization for cervical leiomyomas.","volume":"23","author":"Kim","year":"2012","journal-title":"J Vasc Interv Radiol"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jmig.2017.07.007","article-title":"Minimally invasive approaches to myoma management.","volume":"25","author":"Gingold","year":"2018","journal-title":"J Minim Invasive Gynecol"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.jmig.2020.11.004","article-title":"Uterine artery embolization compared with high-intensity focused ultrasound ablation for the treatment of symptomatic uterine myomas: a systematic review and meta-analysis.","volume":"28","author":"Liu","year":"2021","journal-title":"J Minim Invasive Gynecol"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1186\/s12876-021-01991-3","article-title":"Quantitative splenic embolization possible: application of 8Spheres conformal microspheres in partial splenic embolization (PSE).","volume":"21","author":"Lu","year":"2021","journal-title":"BMC Gastroenterol"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1148\/radiol.2020201895","article-title":"Nonspherical polyvinyl alcohol particles versus tris-acryl microspheres: randomized controlled trial comparing pain after uterine artery embolization for symptomatic fibroids.","volume":"298","author":"Han","year":"2021","journal-title":"Radiology"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1007\/s00270-013-0790-0","article-title":"Comparison of embolic agents used in uterine artery embolisation: a systematic review and meta-analysis.","volume":"37","author":"Das","year":"2014","journal-title":"Cardiovasc Intervent Radiol"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jvir.2007.08.034","article-title":"Leiomyoma infarction after uterine artery embolization: a prospective randomized study comparing tris-acryl gelatin microspheres versus polyvinyl alcohol microspheres.","volume":"19","author":"Siskin","year":"2008","journal-title":"J Vasc Interv Radiol"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1056\/NEJMoa1904351","article-title":"Elagolix for heavy menstrual bleeding in women with uterine fibroids.","volume":"382","author":"Schlaff","year":"2020","journal-title":"N Engl J Med"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1016\/j.jvir.2014.08.029","article-title":"Quality improvement guidelines for uterine artery embolization for symptomatic leiomyomata.","volume":"25","author":"Dariushnia","year":"2014","journal-title":"J Vasc Interv Radiol"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.fertnstert.2018.07.1152","article-title":"Cardiovascular health and ovarian aging.","volume":"110","author":"Quinn","year":"2018","journal-title":"Fertil Steril"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ejogrb.2016.09.001","article-title":"The effects of uterine artery embolization on ovarian reserve.","volume":"206","author":"Kim","year":"2016","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1056\/NEJMcp1411029","article-title":"Clinical practice. Uterine fibroids.","volume":"372","author":"Stewart","year":"2015","journal-title":"N Engl J Med"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.rbmo.2012.07.011","article-title":"Effects of transdermal testosterone in poor responders undergoing IVF: systematic review and meta-analysis.","volume":"25","author":"Gonz\u00e1lez-Comadran","year":"2012","journal-title":"Reprod Biomed Online"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1093\/humrep\/des265","article-title":"The impact of androgen metabolism and FMR1 genotypes on pregnancy potential in women with dehydroepiandrosterone (DHEA) supplementation.","volume":"27","author":"Weghofer","year":"2012","journal-title":"Hum Reprod"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3109\/09513590.2015.1076784","article-title":"Basal serum testosterone levels correlate with ovarian reserve and ovarian response in cycling women undergoingin vitrofertilization.","volume":"32","author":"Xiao","year":"2015","journal-title":"Gynecol Endocrinol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000033099","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T02:36:12Z","timestamp":1746326172000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000033099"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,3]]},"references-count":24,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000033099","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3,3]]}}}